RemeGen
HKEX: 09995 ~HK$55B MCAP
China-based biopharmaceutical company co-founded in 2008 and headquartered in Yantai, developing novel biologics and antibody-drug conjugates. Its marketed products include telitacicept for autoimmune disease and disitamab vedotin for HER2-expressing solid tumors.
Company Info
Sector:Biologics / Antibody-Drug Conjugates
Headquarters:Yantai, Shandong, China
Founded:2008
Website:www.remegen.com/
Clinical Development Pipeline
telitacicept (RC18)
Target: BAFF / APRILdisitamab vedotin (RC48)
Target: HER2RC148
Target: PD-1 / VEGFRecent News
No recent news updates available for this company.
Leadership Team
Dr. Jianmin Fang
Co-Founder, Chief Executive Officer and Chief Scientific Officer
Wang Weidong
Co-Founder
Dr. Daotian Fu
President